CompletedNCT05527964
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Observational studyAges 18+CzechiaAnxiety
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- PragueSee all locations and recruitment
Study information
Study start dateStarted: December 30, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 146
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- Czechia
- Age range
- Over 18 Years
- Official registry ID
- NCT05527964
- Official title
Show the full official title
The Influence of Specific Targeted Therapy on Subject and Family Quality of Life, Anxiety, Depression and Sleep Quality in Patients With Severe Refractory Atopic Dermatitis in the Czech Republic
Get this study by email
Recruitment & locations
CompletedPrague, Czechia · Czechia
Questions about this study
Who is behind this study?
The study sponsor is Sanofi.
Who was this study for?
Listed age limits: from 18 years.
Want to explore more studies?
Explore studiesRelated studies
The Impact of Equine-Assisted Psychotherapy on Depression, Anxiety, and Stress in Patients with Addiction in a Psychiatric Hospital
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER (GAD) SWITCHING FROM BENZODIAZEPINE THERAPY Estudio multicéntrico, alea...